Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants-Reference-Cited by-同舟云学术

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants

Published:2022-12-05 Issue:1 Volume:12 Page:38-56
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Barth Aline¹²,Hossain Mohammad¹³,Perry Caroline R.¹,Gross Annette S.⁴,Ogura Hirofumi⁵,Shabbir Shaila⁶,Thomas Sebin¹,Dumont Etienne F.¹⁷,Brimhall Darin B.⁸,Srinivasan Meenakshi¹,Swift Brandon⁹

Affiliation:

1. GSK Collegeville Pennsylvania USA

2. Present affiliation: Global Blood Therapeutics San Francisco California USA

3. Present affiliation: Servier Pharmaceuticals Boston Massachusetts USA

4. GSK R&D Sydney AU

5. GSK Tokyo Japan

6. GSK Stevenage UK

7. Present affiliation: Boston Pharmaceuticals Cambridge Massachusetts USA

8. PPD Las Vegas Nevada USA

9. GSK Durham North Carolina USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1192

Reference34 articles.

1. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

2. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase

3. Type IIA topoisomerase inhibition by a new class of antibacterial agents

4. Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis);Overcash JS;Antimicrob Agents Chemother,2020

5. MushtaqS VickersA SadoukiZ et al.In vitro activities of gepotidacin a novel triazaacenaphthylene topoisomerase IV and DNA gyrase inhibitor against gram‐negative bacteria andStaphylococcus saprophyticus[poster P1849]. Presented at: the 29th European Congress of Clinical Microbiology & Infectious Diseases; April 13–16 2019;Amsterdam The Netherlands.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SWOT and Root Cause Analyses of Antimicrobial Resistance to Oral Antimicrobial Treatment of Cystitis;Antibiotics;2024-04-04

2. Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea;Journal of Antimicrobial Chemotherapy;2023-03-08